Skip To The Main Content
Parenteral Drug Association Connecting People, Science and Regulation ®

Quality Strategy for Biopharmaceuticals

Apr 06 - Apr 07, 2017 |
Apr 07, 2017 |
Anaheim Marriott | Anaheim, CA
  • Education
Add event to: ICal Outlook Google Calendar
Duration: 2 days
Time: 8:30 a.m. - 4:00 p.m.

Biopharmaceuticals for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and cellular therapy medicinal products. All biological medicines have challenges due to the heightened concern for adventitious agents (e.g., viruses, mycoplasmas), the increased complexity of the impurity profiles (both process- and product-related), and the difficulties encountered in developing a functional (therapeutic) potency assay. But for biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems), the added impacts that clonality and genetic instability might have on the product quality attributes requires sophisticated analytical methods to detect. Nowhere is this better observed than in all of the comparative analytical analyses that biosimilar manufacturers must incorporate into their quality strategy for market approval.

This course will provide insights and practical guidance for those responsible for determining and assuring the required quality for biopharmaceuticals for human use. Using a quality risk-based approach, an effective quality strategy will be explained addressing challenges from Phase 1 clinical studies through commercialization, and for recombinant proteins, monoclonal antibodies, genetically engineered viruses and human cells. The course emphasis will include FDA, EMA and ICH guidance.

Who Should Attend

This 2-day course is designed for management and professional staff involved in or interested in evaluating or developing an effective quality strategy for biopharmaceuticals (recombinant DNA-derived proteins, monoclonal antibodies, gene therapy and cellular therapy medicinal products), including senior management, directors and managers/supervisors, QA/QC, regulatory affairs, manufacturing, process development, and analytical development personnel.

Upon completion of this course, you will be able to:

  • Explain the importance and underlying principles for an effective quality strategy for the various types of biopharmaceuticals – recombinant proteins, monoclonal antibodies, gene therapy and cellular therapy medicines – through clinical development into the marketplace
  • Describe the importance and underlying quality principles for biopharmaceuticals leading regulatory agencies (FDA, EMA) to have different regulatory quality requirements for these products compared to pharmaceuticals of chemical origin



On or before February 20, 2017

After February 20, 2017


On or before February 20, 2017

After February 20, 2017

Government/Health Authority/Academic



All rates in US Dollars. REFUND FOR COURSES: If your written request is received by March 7, 2017, you will receive a full refund less a $200 processing fee. After that time, no refunds will be approved. COURSE CANCELLATION: PDA reserves the right to modify the material or instructors without notice, or to cancel an event. If an event must be cancelled, registrants will be notified by PDA as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to cancellation. For more details, contact PDA at or +1 (301) 656-5900.

Class Schedule

All lab courses begin at 8:30 a.m. and end at 4:00 p.m. unless otherwise noted on the confirmation letter or in course information posted on the website or in the course brochures. Courses that are listed with a half day will begin at 8:30 a.m. and end at noon on the last day.

Please arrive at your course location approximately thirty minutes before the start of the course to sign in. Please be sure to bring your confirmation letter as proof of registration. PDA will not allow persons to attend a course without payment, or guarantee of payment.

A continental breakfast will be served before class beginning 8:00 a.m. Lunch will be provided from 12:00 - 1:00 p.m. Snacks will be provided during the morning break from 10:00 - 10:15 a.m. and the afternoon break from 2:30 - 2:45 p.m.


This course will take place at:

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Phone: +1 (714) 622-3056


For more information, please contact:

Stephanie Ko
Senior Manager, Lecture Education
Tel: +1 (301) 656-5900 x151

John Geigert, President, BioPharmaceutical Quality Solutions

John Geigert is President of BioPharmaceutical Quality Solutions, which for the last 15 years has specialized in providing CMC regulatory strategy consulting for the biopharmaceutical industry. He has over 40 years of CMC industrial experience and leadership in the biopharmaceutical industry. He has held senior management positions as Vice President of Quality at both IDEC Pharmaceuticals Corporation in San Diego and Immunex Corporation in Seattle, and he was Director of Product Development at Cetus Corporation in Berkeley. At these companies, he helped lead the CMC efforts to obtain regulatory approvals for 6 biopharmaceutical products now commercially available in the U.S. and in Europe. John Geigert has served on the PDA Board of Directors, currently chairs the PDA Biopharmaceutical Advisory Board, and has served as an expert member of the USP Biotechnology Committee. He is the author of the book The Challenge of CMC Regulatory Compliance for Biopharmaceuticals and Other Biologics 2nd Edition, and has written extensively for RAPS Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series)), Demystifying CMC Regulatory Strategy (Sept 2011-Mar 2012, 4-part series). John Geigert obtained his B.S. in Chemistry from Washington State University and his Ph.D. degree in Organic/Analytical Chemistry from Colorado State University.

Continuing Education for Pharmacists

ACPE PDA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants may sign up to receive Continuing Pharmacy Education (CPE) credits. To do so, participants must sign in at the beginning of the program, submit the provided evaluation forms and mail the CPE credit request to the address stated on the form. Attendees must be present at the full event to receive Continuing Pharmacy Education credit, which will be awarded as follows:

PDA #448 | ACPE #0116-0000-16-029-L04-P | 1.2 CEUs
Type of Activity: Knowledge

Continuing Education for Professional Engineers

New Jersey

PDA is an approved provider by the New Jersey State Board of Professional Engineers and Land Surveyors to offer courses to New Jersey Professional Engineers for Continuing Professional Competency (CPC) credit. Following the full participation in this course, participants will receive a Certificate of Accomplishment specifying the number of CPC credits that may be awarded. This certificate can be submitted as verification of completion to the Board for license renewal.

The credit value of this course is 12 CPC credits.

North Carolina

PDA is recognized by the North Carolina Board of Examiners for Engineers and Surveyors as an Approved Sponsor of Continuing Professional Competency (CPC) activities for Professional Engineers licensed by North Carolina. To receive a Certificate of Accomplishment specifying the number of Professional Development Hours (PDHs) that may be awarded, course participants must request the North Carolina Board of Examiners evaluation form from PDA staff. This form must be completed onsite at the conclusion of the course and returned to PDA staff.

The credit value of this course is 12 PDHs.